fda warning letters compounded semaglutide september 2025 issued 25 to telehealth companies for false and misleading claims about GLP-1 products. Unlike FDA-approved drugs, these products have not been proven to be safe, effective, or of U.S. FDA sends drug advertising

"Patients finally have an obesity treatment available to them that actually works -- but because of ongoing challenges with supply -- they have to literally hunt down their medication, sometimes calling every pharmacy in their city just to come up empty," he wrote

Dietary considerations Semaglutide reduces appetite

[DOI] [PubMed] [Google Scholar] 98.Yaribeygi H., Sathyapalan T., Atkin S.L., Sahebkar A

GIP (glucose-dependent insulinotropic polypeptide) receptor

risk management

Second Natures published outcomes data shows members on our GLP-1 programmes lose an average of 19.1% of their starting body weight at 12 months, with 77.7% achieving a clinically meaningful loss of 10% or more